- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05470933
A Study Explore WJ01075 Tablets in Patients With Advanced Solid Tumors
A Phase Ⅰ Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of WJ01075 Tablets in Oral Dose Escalation and Expansion in Patients With Advanced Solid Tumors
This is a phase I study to Investigate the safety and tolerability, DLT(Dose limited toxicity), MTD(Maximum tolerated dose), and RP2D(Recommended phase II dose) of WJ01075 tablets in patients with advanced malignant solid tumors, including phase Ia (dose escalation phase) and Phase Ib (dose expansion phase,cohort expansion phase).The study includes screening, treatment and follow-up periods.
In phase Ia, accelerated titration (the first two dose groups) and "3 + 3" combination (the subsequent dose group) were used for dose escalation.
In phase Ib, specific dose groups will be selected for dose expansion according to PK(Pharmacokinetics) and safety data of different dose groups in dose escalation phase.It is planned that SMC(Safety Monitoring Committee) will select one or more dose groups based on previous data for cohort expansion studies to further determine RP2D, safety tolerability and initial efficacy.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Jiexin Hu, PM
- Phone Number: 8613521183167
- Email: jiexin_hu@junshipharma.com
Study Locations
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150081
- Harbin Medical University Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient with advanced malignant solid tumors clearly diagnosed pathologically and/or cytologically, who have failed to receive standard treatment, or who currently do not/or refuse standard treatment, or who are intolerant to standard treatment;
- Patient must have at least one measurable lesion as defined per RECIST v1.1;
- Aged between 18 and 75 (including 18 and 75), male and female patients;
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score ≤1;
- Life expectancy ≥ 3 months;
The functions of patients' major organs were basically normal, and the laboratory tests performed within 7 days prior to the first administration of study drugmet the following criteria, Patients must not have required a blood transfusion or growth factor support within 14 days before the examination:
Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤2.5 × Upper limit of Normal (ULN); Total Bilirubin≤ 1.5×ULN; International Normalized Ratio (INR) ≤1.5; Creatinine ≤ 1.5 × ULN, and Creatinine Clearance Rate (calculated by Cockcroft-Gault formula) ≥ 50 mL/min; Hemoglobin (Hg) ≥ 90g/L; Platelets ≥ 100×10⋀9/L; Absolute Neutrophil Count(ANC) ≥ 1.5×10⋀9/L
- Fertile women must confirm a negative blood pregnancy test within 7 days prior to the first administration of study drug;All enrolled patients (both male and female) are required to use adequate and effective contraceptive measures throughout the treatment period and within 3 months after the end of treatment;
- Those who voluntarily participate in the study and sign the written Informed Consent Form upon full informed consent.
Exclusion Criteria:
- Prior treatment with XPO1 inhibitors;
- Have a history of allergy to any component or excipient of WJ010175 tablets;
- Patient with a primary malignancy other than the tumor treated in the study within 5 years prior to the first administration of study drug (exceptions include cured malignancies that did not recur within 3 years prior to enrollment;Basal cell and squamous cell carcinoma completely resected;Complete excision of any type of carcinoma in situ, etc.);
- Received other anti-tumor therapies, including but not limited to chemotherapy, radiotherapy, targeted therapy, immunotherapy and other anti-tumor therapies (such as anti-tumor traditional Chinese medicine), within 4 weeks or 5 half-life periods (whichever is longer) prior to the first administration of study drug;Or long-term treatment with potent CYP1A2 inhibitors, potent CYP3A4 inducers and potent CYP3A4 inhibition;
- Thrombosis or embolism occurred within 6 months prior to the first administration of study drug;
- Received medium or major surgical treatment within 4 weeks prior to the first administration of study drug, other than diagnostic biopsy ;
- Any of the following conditions within 6 months prior to the first administration of study drug: New York Cardiology Association (NYHA) > Grade II cardiac insufficiency, congestive heart failure, severe/unstable angina pectoris (symptoms of resting angina pectoris), myocardial infarction, arrhythmias requiring treatment, uncontrolled hypertension or hypertensive crisis or hypertensive encephalopathy;
- Adverse events and/or complications caused by previous treatment are not relieved to < Level 2 (per NCI-CTCAE V5.0);Any level of hair loss/pigmentation and long-term toxicity caused by other treatment, other than those that the investigator diagnosiss cannot be recovered and do not affect study administration or compliance and patient safety;
- Patient with central nervous system metastasis or tumors originating in the central nervous system;,
- Patient with grade ≥ 2 neuropathy (per NCI-CTCAE V5.0);
- Severe infections requiring antibiotic treatment within 14 days prior to the first administration of study drug ( > CTCAE Grade 2 ), such as severe pneumonia, bacteremia, infection complications requiring hospitalization;
- Uncontrolled pericardial effusion, pleural effusion or clinically obvious moderate to severe abdominal effusion during screening is defined as meeting the following criteria: having clinical symptoms and detectable thoracic and abdominal effusion during physical examination;Or in the screening process, the thoracoabdominal effusion needs to be punctured pumping liquid and/or intravenously administered;
- Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
- Patient has serious psychological or mental abnormalities affecting the compliance of the subjects to participate in the study;
- With active Hepatitis B, or Hepatitis C, or Human Immunodeficiency Virus positive [HIV (+)] and syphilis antibody (+);Note: Hepatitis B virus surface Antigen (HBsAg) or core antibody (HBcAb) positive should be tested for HBV-DNA, and HBV-DNA should be below the lower limit of the reference range.Patients who are positive for Hepatitis C virus Antibody (HCV Ab) will be tested for HCV RNA and can be enrolled if they are below the upper limit of normal.
- With Gastrointestinal dysfunction that may affect drug absorption (e.g., intestinal obstruction, inability to swallow tablets, malabsorption syndrome, uncontrollable nausea or vomiting, etc.);
- Pregnant or lactating women or men who still have reproductive needs;
- Other conditions that the investigator considers to be ineligible for inclusion, including but not limited to subjects whose body weight is less than ideal and who are expected to be significantly affected by weight change as determined by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: WJ01075 tablets
Once a week (QW).
|
Phase Ia: Dose Escalation Accelerated titration (the first two dose groups) and "3 + 3" combination (the subsequent dose group) were used for dose escalation. Phase Ib: Dose Expansion and Cohort Expansion The actual dose, dosing schedule (including combination) and indication selection will be evaluated based on the results of existing trials. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose limited toxicity (DLT)
Time Frame: 3 years
|
incidence and severity of Dose limited toxicity(DLT);
|
3 years
|
Adverse event (AE)
Time Frame: 3 years
|
incidence and severity of adverse event (AE), Abnormal changes in laboratory and other tests of clinical significance;
|
3 years
|
Serious adverse event (SAE)
Time Frame: 3 years
|
incidence and severity of Serious adverse event (SAE);
|
3 years
|
Maximum tolerated dose (MTD)
Time Frame: 2 years
|
Maximum tolerated dose (MTD)
|
2 years
|
Recommended phase II dose (RP2D)
Time Frame: 2 years
|
Recommended phase II dose (RP2D)
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate(ORR)
Time Frame: 2 years
|
Efficacy endpoints: Objective response rate(ORR) per RECIST v1.1
|
2 years
|
Duration of response (DOR)
Time Frame: 2 years
|
Efficacy endpoints: Duration of response (DOR) per RECIST v1.1
|
2 years
|
Disease control rate (DCR)
Time Frame: 2 years
|
Efficacy endpoints: Disease control rate (DCR) per RECIST v1.1
|
2 years
|
Time to response(TTR)
Time Frame: 2 years
|
Efficacy endpoints: Time to response(TTR) per RECIST v1.1
|
2 years
|
Progression-free survival (PFS)
Time Frame: 2 years
|
Efficacy endpoints: Progression-free survival (PFS) per RECIST v1.1
|
2 years
|
Overall survival (OS)
Time Frame: 2 years
|
Efficacy endpoints: Overall survival (OS) per RECIST v1.1
|
2 years
|
Peak time(Tmax)
Time Frame: 2 years
|
Pharmacokinetic (PK) parameter : Peak time(Tmax) after a single dose;
|
2 years
|
Maximum plasma concentration (Cmax)
Time Frame: 2 years
|
Pharmacokinetic (PK) parameter : Maximum plasma concentration (Cmax) after a single dose;
|
2 years
|
Clearance rate (CL/F)
Time Frame: 2 years
|
Pharmacokinetic (PK) parameter : Clearance rate (CL/F) after a single dose;
|
2 years
|
Apparent volume of distribution (Vd/F)
Time Frame: 2 years
|
Pharmacokinetic (PK) parameter : Apparent volume of distribution (Vd/F) after a single dose;
|
2 years
|
Area under blood concentration - time curve (AUC)
Time Frame: 2 years
|
Pharmacokinetic (PK) parameter : Area under blood concentration - time curve (AUC) after a single dose;
|
2 years
|
Elimination rate constant (λz)
Time Frame: 2 years
|
Pharmacokinetic (PK) parameter : Elimination rate constant (λz) after a single dose;
|
2 years
|
Elimination half-life time ( t1/2) and other parameters
Time Frame: 2 years
|
Pharmacokinetic (PK) parameter : Elimination half-life time ( t1/2) and other parameters after a single dose;
|
2 years
|
Steady state valley concentration(Cssmin)
Time Frame: 2 years
|
Pharmacokinetic (PK) parameter : Steady state valley concentration(Cssmin) after repeated administration;
|
2 years
|
Steady state peak concentration(Cssmax)
Time Frame: 2 years
|
Pharmacokinetic (PK) parameter : Steady state peak concentration(Cssmax) after repeated administration;
|
2 years
|
Average steady-state plasma concentration(Css-av)
Time Frame: 2 years
|
Pharmacokinetic (PK) parameter : Average steady-state plasma concentration(Css-av) after repeated administration;
|
2 years
|
Elimination half-life time ( t1/2)
Time Frame: 2 years
|
Pharmacokinetic (PK) parameter : Elimination half-life time ( t1/2) after repeated administration;
|
2 years
|
Steady state Area under blood concentration - time curve(AUCss)
Time Frame: 2 years
|
Pharmacokinetic (PK) parameter : Steady state Area under blood concentration - time curve(AUCss) after repeated administration;
|
2 years
|
Fluctuation coefficient (DF)
Time Frame: 2 years
|
Pharmacokinetic (PK) parameter : Fluctuation coefficient (DF) after repeated administration;
|
2 years
|
Steady-state distribution volume(Vss )
Time Frame: 2 years
|
Pharmacokinetic (PK) parameter : Steady-state distribution volume(Vss ) after repeated administration;
|
2 years
|
Accumulation coefficient (AR) and other parameters
Time Frame: 2 years
|
Pharmacokinetic (PK) parameter : Accumulation coefficient (AR) and other parameters after repeated administration;
|
2 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JS124-001-I
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia